3,055 results on '"Kesselheim, Aaron"'
Search Results
2. Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies
3. Measuring and Understanding Market Exclusivity Length for New Prescription Drugs in France, Australia, and the USA
4. Evidence, Errors, and Ethics
5. Physician and Device Manufacturer Tort Liability for Remote Patient Monitoring Devices
6. The cost of drug patent expiration date errors
7. Biologic patent challenges under the America Invents Act
8. Independent Advice on Drug Approvals: an Investigation of EMA Practices
9. Approval and therapeutic value of gene therapies in the US and Europe
10. Experts’ Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care
11. The prevalence of drug patent term extensions in the United States, 2000–2018
12. Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma
13. Clinical Benefit and Revenues of Drugs Affected by Rare Pediatric Disease Priority Review Vouchers, 2017-2023
14. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework
15. Rates and costs of drug testing practices for private payors in the outpatient setting in the United States, 2015–2019
16. Market dynamics of authorized generics in Medicaid from 2014 to 2020
17. Ethical issues in new drug prescribing
18. Persistence of resistance: a panel data analysis of the effect of antibiotic usage on the prevalence of resistance
19. Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014
20. Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
21. Alternatives to the quality-adjusted life year: How well do they address common criticisms?
22. Coverage of New Drugs in Medicare Part D
23. Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019
24. Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease
25. Patenting Strategies on Inhaler Delivery Devices
26. Getting the Price Right: Lessons for Medicare Price Negotiation from Peer Countries
27. Pursuing Value-Based Prices for Drugs : A Comprehensive Comparison of State Prescription Drug–Pricing Boards
28. Using Multiple Authorized Generics to Maintain High Prices: The Example of Entacapone
29. Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD
30. Medicaid Expenditures and Estimated Rebates on Line Extension Drugs, 2010–2018
31. Regulating Laboratory Tests: What Framework Would Best Support Safety and Validity?
32. Global cooperation and early access—clinical outcomes matter
33. Use of Efficiency Frontiers to Align Prices and Clinical Benefits of Biologic Therapies for Plaque Psoriasis
34. New Drug Postmarketing Requirements and Commitments in the US: A Systematic Review of the Evidence
35. State Laws and Generic Substitution in the Year After New Generic Competition
36. Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis
37. The characteristics of patents impacting availability of biosimilars
38. Why France Spends Less Than the United States on Drugs : A Comparative Study of Drug Pricing and Pricing Regulation
39. Ensuring Patient Safety and Benefit in Use of Medical Devices Granted Expedited Approval
40. Lifecycle Regulation and Evaluation of Artificial Intelligence and Machine Learning-Based Medical Devices
41. Patient perspectives on evidence supporting drug safety and effectiveness: "What does it mean for me?".
42. Commercial markups on pediatric oncology drugs at 340B pediatric hospitals.
43. Clinical value of guideline recommended molecular targets and genome targeted cancer therapies: cross sectional study.
44. Trust in the Food and Drug Administration: A National Survey Study.
45. Patent Portfolios Protecting 10 Top-Selling Prescription Drugs.
46. Producing and using timely comparative evidence on drugs : lessons from clinical trials for covid-19
47. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines : retrospective cohort study
48. Accounting for US public funding in drug development : how can we better balance access, affordability, and innovation?
49. Characteristics of US Patients and Prescribers Using Hydroxychloroquine During the COVID-19 Pandemic
50. Patient Out-of-Pocket Costs for Biologic Drugs After Biosimilar Competition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.